Published in Circulation on August 01, 2011
Removal of Anti-Angiogenic Proteins in Preeclampsia Before Delivery (RAAPID-II) | NCT01404910
Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature (2012) 2.27
Clinical characterization and outcomes of preeclampsia with normal angiogenic profile. Hypertens Pregnancy (2013) 2.22
The course of angiogenic factors in early- vs. late-onset preeclampsia and HELLP syndrome. J Perinat Med (2013) 2.06
Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation (2012) 1.88
Recent advances in the understanding of the pathophysiology of preeclampsia. Hypertension (2013) 1.71
The role of the podocyte in albumin filtration. Nat Rev Nephrol (2013) 1.26
Removal of Soluble Fms-Like Tyrosine Kinase-1 by Dextran Sulfate Apheresis in Preeclampsia. J Am Soc Nephrol (2015) 1.25
A comprehensive review of hypertension in pregnancy. J Pregnancy (2012) 1.16
Angiogenic factors in diagnosis, management, and research in preeclampsia. Hypertension (2013) 1.11
Is inflammation the cause of pre-eclampsia? Biochem Soc Trans (2011) 1.09
Maternal plasma concentrations of angiogenic/antiangiogenic factors in the third trimester of pregnancy to identify the patient at risk for stillbirth at or near term and severe late preeclampsia. Am J Obstet Gynecol (2013) 1.05
Advances in the pathophysiology of pre-eclampsia and related podocyte injury. Kidney Int (2014) 1.03
Hydrogen sulfide attenuates sFlt1-induced hypertension and renal damage by upregulating vascular endothelial growth factor. J Am Soc Nephrol (2013) 1.03
A lesson for cancer research: placental microarray gene analysis in preeclampsia. Oncotarget (2012) 0.99
New developments in the pathogenesis of preeclampsia. Adv Chronic Kidney Dis (2013) 0.97
Therapeutic potential of statins and the induction of heme oxygenase-1 in preeclampsia. J Reprod Immunol (2014) 0.96
Pathophysiology of hypertension in pre-eclampsia: a lesson in integrative physiology. Acta Physiol (Oxf) (2013) 0.96
Plasma concentrations of soluble endoglin versus standard evaluation in patients with suspected preeclampsia. PLoS One (2012) 0.94
Angiotensin II type 1 receptor autoantibody (AT1-AA)-mediated pregnancy hypertension. Am J Reprod Immunol (2012) 0.93
Linking placental ischemia and hypertension in preeclampsia: role of endothelin 1. Hypertension (2012) 0.93
Treatment of poor placentation and the prevention of associated adverse outcomes--what does the future hold? Prenat Diagn (2014) 0.92
Endometrial VEGF induces placental sFLT1 and leads to pregnancy complications. J Clin Invest (2014) 0.92
VEGFR and type-V RTK activation and signaling. Cold Spring Harb Perspect Biol (2013) 0.91
Pre-eclampsia: its pathogenesis and pathophysiolgy. Cardiovasc J Afr (2016) 0.88
Evidence of an imbalance of angiogenic/antiangiogenic factors in massive perivillous fibrin deposition (maternal floor infarction): a placental lesion associated with recurrent miscarriage and fetal death. Am J Obstet Gynecol (2013) 0.87
Impaired adenosine-mediated angiogenesis in preeclampsia: potential implications for fetal programming. Front Pharmacol (2014) 0.86
Maternally sequestered therapeutic polypeptides - a new approach for the management of preeclampsia. Front Pharmacol (2014) 0.83
New approaches for managing preeclampsia: clues from clinical and basic research. Clin Ther (2014) 0.83
Endothelin as a final common pathway in the pathophysiology of preeclampsia: therapeutic implications. Curr Opin Nephrol Hypertens (2012) 0.83
The elevation in circulating anti-angiogenic factors is independent of markers of neutrophil activation in preeclampsia. Angiogenesis (2012) 0.82
Preeclampsia - Aetiology, Current Diagnostics and Clinical Management, New Therapy Options and Future Perspectives. Geburtshilfe Frauenheilkd (2012) 0.81
Endoglin: a critical mediator of cardiovascular health. Vasc Health Risk Manag (2013) 0.81
Low-molecular weight heparin increases circulating sFlt-1 levels and enhances urinary elimination. PLoS One (2014) 0.81
The maternal brain: an organ with peripartal plasticity. Neural Plast (2014) 0.80
Cardio-Oncology: How New Targeted Cancer Therapies and Precision Medicine Can Inform Cardiovascular Discovery. Circulation (2015) 0.80
In vivo experiments reveal the good, the bad and the ugly faces of sFlt-1 in pregnancy. PLoS One (2014) 0.80
Angiogenic factors in preeclampsia: potential for diagnosis and treatment. Curr Opin Nephrol Hypertens (2013) 0.79
Oxidative Stress in Placenta: Health and Diseases. Biomed Res Int (2015) 0.79
Placental disease and the maternal syndrome of preeclampsia: missing links? Curr Hypertens Rep (2013) 0.79
Aspirin inhibits expression of sFLT1 from human cytotrophoblasts induced by hypoxia, via cyclo-oxygenase 1. Placenta (2015) 0.78
Letter by Winkler et al regarding article, "Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia". Circulation (2012) 0.78
Preeclampsia from a renal point of view: Insides into disease models, biomarkers and therapy. World J Nephrol (2014) 0.78
Endoglin in liver fibrogenesis: Bridging basic science and clinical practice. World J Biol Chem (2014) 0.78
Molecular Mechanisms of Preeclampsia. Cold Spring Harb Perspect Med (2015) 0.78
Modeling risk for severe adverse outcomes using angiogenic factor measurements in women with suspected preterm preeclampsia. Prenat Diagn (2015) 0.78
Placental Growth Factor Reduces Blood Pressure in a Uteroplacental Ischemia Model of Preeclampsia in Nonhuman Primates. Hypertension (2016) 0.78
Prediction of preeclampsia and induced delivery at <34 weeks gestation by sFLT-1 and PlGF in patients with abnormal midtrimester uterine Doppler velocimetry: a prospective cohort analysis. BMC Pregnancy Childbirth (2014) 0.77
Relaxin Treatment in an Ang-II-Based Transgenic Preeclamptic-Rat Model. PLoS One (2016) 0.77
Preeclampsia - will orphan drug status facilitate innovative biological therapies? Front Surg (2015) 0.76
A Dormant Microbial Component in the Development of Preeclampsia. Front Med (Lausanne) (2016) 0.76
Ouabain inhibits placental sFlt1 production by repressing HSP27-dependent HIF-1α pathway. FASEB J (2014) 0.76
Regulatory T cells ameliorate intrauterine growth retardation in a transgenic rat model for preeclampsia. Hypertension (2015) 0.76
Sodium hydrosulfide prevents hypertension and increases in vascular endothelial growth factor and soluble fms-like tyrosine kinase-1 in hypertensive pregnant rats. Naunyn Schmiedebergs Arch Pharmacol (2016) 0.75
Response to Plasmapheresis Measured by Angiogenic Factors in a Woman with Antiphospholipid Syndrome in Pregnancy. Case Rep Obstet Gynecol (2015) 0.75
Pathophysiology of preeclampsia: an angiogenic imbalance and long-lasting systemic vascular dysfunction. Hypertens Res (2016) 0.75
Letter by Espinoza regarding article, "Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia". Circulation (2012) 0.75
Hypertension: sFlt-1 removal seems to be beneficial in women with pre-eclampsia. Nat Rev Nephrol (2015) 0.75
Effects of simvastatin, rosuvastatin and pravastatin on soluble fms-like tyrosine kinase 1 (sFlt-1) and soluble endoglin (sENG) secretion from human umbilical vein endothelial cells, primary trophoblast cells and placenta. BMC Pregnancy Childbirth (2016) 0.75
Placental Growth Factor, Soluble fms-Like Tyrosine Kinase 1, Soluble Endoglin, IL-6, and IL-16 as Biomarkers in Preeclampsia. Mediators Inflamm (2016) 0.75
Double blind, randomised, placebo-controlled trial to evaluate the efficacy of esomeprazole to treat early onset pre-eclampsia (PIE Trial): a study protocol. BMJ Open (2015) 0.75
GPCRs as potential therapeutic targets in preeclampsia. Drug Discov Today Dis Models (2012) 0.75
Hypertension: Testing for pre-eclampsia: paving the way to early diagnosis. Nat Rev Nephrol (2016) 0.75
Response to Letter Regarding Article, "Elevated Placental Adenosine Signaling Contributes to the Pathogenesis of Preeclampsia". Circulation (2015) 0.75
A mammalian microRNA expression atlas based on small RNA library sequencing. Cell (2007) 34.03
Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med (2004) 14.00
Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest (2003) 13.72
Vitamin D-binding protein and vitamin D status of black Americans and white Americans. N Engl J Med (2013) 9.87
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet (2007) 9.24
When cilia go bad: cilia defects and ciliopathies. Nat Rev Mol Cell Biol (2007) 8.28
Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med (2004) 8.11
Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med (2006) 7.06
Inversin, the gene product mutated in nephronophthisis type II, functions as a molecular switch between Wnt signaling pathways. Nat Genet (2005) 6.67
Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med (2011) 6.35
Ciliopathies. N Engl J Med (2011) 6.28
Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med (2006) 6.21
Mutations in INVS encoding inversin cause nephronophthisis type 2, linking renal cystic disease to the function of primary cilia and left-right axis determination. Nat Genet (2003) 5.24
Mutations in a novel gene, NPHP3, cause adolescent nephronophthisis, tapeto-retinal degeneration and hepatic fibrosis. Nat Genet (2003) 4.14
Excess circulating angiopoietin-2 may contribute to pulmonary vascular leak in sepsis in humans. PLoS Med (2006) 3.72
Ischemic preconditioning for prevention of contrast medium-induced nephropathy: randomized pilot RenPro Trial (Renal Protection Trial). Circulation (2012) 3.42
A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med (2008) 3.39
Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet (2007) 3.11
Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. N Engl J Med (2016) 2.99
Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood (2005) 2.97
Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension (2007) 2.77
Urinary placental growth factor and risk of preeclampsia. JAMA (2005) 2.76
Vascular endothelial growth factor is an important determinant of sepsis morbidity and mortality. J Exp Med (2006) 2.75
Loss of nephrocystin-3 function can cause embryonic lethality, Meckel-Gruber-like syndrome, situs inversus, and renal-hepatic-pancreatic dysplasia. Am J Hum Genet (2008) 2.74
Bioavailable vitamin D is more tightly linked to mineral metabolism than total vitamin D in incident hemodialysis patients. Kidney Int (2012) 2.74
Propofol as an induction agent for endotracheal intubation can cause significant arterial hypotension in preterm neonates. Paediatr Anaesth (2010) 2.72
Vascular endothelial growth factor-A and aldosterone: relevance to normal pregnancy and preeclampsia. Hypertension (2013) 2.70
Nephrin and CD2AP associate with phosphoinositide 3-OH kinase and stimulate AKT-dependent signaling. Mol Cell Biol (2003) 2.69
Podocyte-specific deletion of dicer alters cytoskeletal dynamics and causes glomerular disease. J Am Soc Nephrol (2008) 2.69
Pathogenesis of preeclampsia. Annu Rev Pathol (2010) 2.66
Mutations in the cilia gene ARL13B lead to the classical form of Joubert syndrome. Am J Hum Genet (2008) 2.65
Increased cardiovascular disease risk indices in HIV-infected women. J Acquir Immune Defic Syndr (2005) 2.63
Avoidance of mechanical ventilation by surfactant treatment of spontaneously breathing preterm infants (AMV): an open-label, randomised, controlled trial. Lancet (2011) 2.62
Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia. Hypertension (2007) 2.62
Vitamin D-binding protein modifies the vitamin D-bone mineral density relationship. J Bone Miner Res (2011) 2.55
Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation (2011) 2.55
Exome capture reveals ZNF423 and CEP164 mutations, linking renal ciliopathies to DNA damage response signaling. Cell (2012) 2.54
On the nucleation of amyloid beta-protein monomer folding. Protein Sci (2005) 2.47
Angiopoietin-2 may contribute to multiple organ dysfunction and death in sepsis*. Crit Care Med (2012) 2.32
Vitamin D deficiency and cardiovascular events in patients with coronary heart disease: data from the Heart and Soul Study. Am J Epidemiol (2014) 2.30
Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature (2012) 2.27
Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci U S A (2007) 2.25
Clinical characterization and outcomes of preeclampsia with normal angiogenic profile. Hypertens Pregnancy (2013) 2.22
Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. Hypertension (2005) 2.22
Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med (2015) 2.18
Early outcomes among those initiating chronic dialysis in the United States. Clin J Am Soc Nephrol (2011) 2.17
Podocin and MEC-2 bind cholesterol to regulate the activity of associated ion channels. Proc Natl Acad Sci U S A (2006) 2.16
Trafficking of TRPP2 by PACS proteins represents a novel mechanism of ion channel regulation. EMBO J (2005) 2.12
First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab (2004) 2.11
Preeclampsia: the role of angiogenic factors in its pathogenesis. Physiology (Bethesda) (2009) 2.10
Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients. Drugs (2007) 2.09
Angiopoietin 2 is a partial agonist/antagonist of Tie2 signaling in the endothelium. Mol Cell Biol (2009) 2.09
The course of angiogenic factors in early- vs. late-onset preeclampsia and HELLP syndrome. J Perinat Med (2013) 2.06
Preeclampsia and angiogenic imbalance. Annu Rev Med (2008) 2.05
Circulating levels of the antiangiogenic marker sFLT-1 are increased in first versus second pregnancies. Am J Obstet Gynecol (2005) 2.03
The slit diaphragm: a signaling platform to regulate podocyte function. Curr Opin Nephrol Hypertens (2005) 2.02
Endothelial dysfunction: a link among preeclampsia, recurrent pregnancy loss, and future cardiovascular events? Hypertension (2006) 2.02
Mutations in the gene encoding the lamin B receptor produce an altered nuclear morphology in granulocytes (Pelger-Huët anomaly). Nat Genet (2002) 1.99
Nephrin mutations can cause childhood-onset steroid-resistant nephrotic syndrome. J Am Soc Nephrol (2008) 1.94
An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol (2009) 1.92
Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study. Haematologica (2010) 1.91
Molecular mechanisms of preeclampsia. Microvasc Res (2007) 1.90
PGC-1α promotes recovery after acute kidney injury during systemic inflammation in mice. J Clin Invest (2011) 1.88
Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation (2012) 1.88
Transcriptionally active syncytial aggregates in the maternal circulation may contribute to circulating soluble fms-like tyrosine kinase 1 in preeclampsia. Hypertension (2012) 1.86
PDZD7 is a modifier of retinal disease and a contributor to digenic Usher syndrome. J Clin Invest (2010) 1.85
Escobar syndrome is a prenatal myasthenia caused by disruption of the acetylcholine receptor fetal gamma subunit. Am J Hum Genet (2006) 1.84
Homodimerization and heterodimerization of the glomerular podocyte proteins nephrin and NEPH1. J Am Soc Nephrol (2003) 1.83
Recombinant vascular endothelial growth factor 121 infusion lowers blood pressure and improves renal function in rats with placentalischemia-induced hypertension. Hypertension (2009) 1.82
Diagnostic utility of soluble fms-like tyrosine kinase 1 and soluble endoglin in hypertensive diseases of pregnancy. Am J Obstet Gynecol (2007) 1.80
Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome. Pharmacotherapy (2008) 1.79
Nephrocystin specifically localizes to the transition zone of renal and respiratory cilia and photoreceptor connecting cilia. J Am Soc Nephrol (2006) 1.79
Soluble Fms-like tyrosine kinase 1 and endothelial dysfunction in the pathogenesis of preeclampsia. Pediatr Res (2005) 1.78
Kelch-like homologue 9 mutation is associated with an early onset autosomal dominant distal myopathy. Brain (2010) 1.76
Uric acid, endothelial dysfunction and pre-eclampsia: searching for a pathogenetic link. J Hypertens (2004) 1.71
Molecular basis of the functional podocin-nephrin complex: mutations in the NPHS2 gene disrupt nephrin targeting to lipid raft microdomains. Hum Mol Genet (2003) 1.70
Pathophysiology of the clinical manifestations of preeclampsia. Clin J Am Soc Nephrol (2007) 1.69
Structural basis of membrane binding by Gla domains of vitamin K-dependent proteins. Nat Struct Biol (2003) 1.68
Pre-eclampsia: clinical manifestations and molecular mechanisms. Nephron Clin Pract (2007) 1.67
Cytomegalovirus-induced mirror syndrome associated with elevated levels of circulating antiangiogenic factors. Obstet Gynecol (2007) 1.67
The von Hippel-Lindau tumor suppressor protein controls ciliogenesis by orienting microtubule growth. J Cell Biol (2006) 1.66
Patients at high risk of invasive fungal infections: when and how to treat. Drugs (2008) 1.62
Central venous catheter (CVC)-related infections in neutropenic patients--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol (2003) 1.62
Interferon-α and angiogenic dysregulation in pregnant lupus patients who develop preeclampsia. Arthritis Rheumatol (2015) 1.61
Mutations in KIF7 link Joubert syndrome with Sonic Hedgehog signaling and microtubule dynamics. J Clin Invest (2011) 1.60
Pre-eclampsia, soluble fms-like tyrosine kinase 1, and the risk of reduced thyroid function: nested case-control and population based study. BMJ (2009) 1.59
Angiogenic factors and preeclampsia. Semin Nephrol (2011) 1.58
Low-dose physiological growth hormone in patients with HIV and abdominal fat accumulation: a randomized controlled trial. JAMA (2008) 1.58
Familial Alzheimer's disease mutations alter the stability of the amyloid beta-protein monomer folding nucleus. Proc Natl Acad Sci U S A (2007) 1.55
Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis (2006) 1.54
Outcome of extremely low gestational age newborns after introduction of a revised protocol to assist preterm infants in their transition to extrauterine life. Acta Paediatr (2012) 1.54
VEGF and TGF-beta are required for the maintenance of the choroid plexus and ependyma. J Exp Med (2008) 1.54
Survival and major neonatal complications in infants born between 22 0/7 and 24 6/7 weeks of gestation (1999-2003). Am J Obstet Gynecol (2006) 1.53
Does the enteral feeding advancement affect short-term outcomes in very low birth weight infants? J Pediatr Gastroenterol Nutr (2009) 1.53
Endostatin causes G1 arrest of endothelial cells through inhibition of cyclin D1. J Biol Chem (2002) 1.51
The glomerular injury of preeclampsia. J Am Soc Nephrol (2007) 1.50
The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am J Obstet Gynecol (2011) 1.50